MedWatch

Sage Therapeutics depression drug disappoints

New data from trial involving a drug treating severe depression disappoints the stock market, and biotech company Sage Therapeutics faces share price decline.

Photo: CARLO ALLEGRI/REUTERS / X90181

Sage Therapeutics took an 18.8 percent dive to USD 59.15 in the US pre-market after the US biotech firm generated disappointing results from a trial involving a potential treatment for severe depression.

Bloomberg News highlights that this late-stage trial, completed in collaboration with Biogen, reached its primary endpoint with improved depression symptoms, whereas the long-term effect was one of the major concerns ahead of the trial results being published.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs